Back to search results

Study of PhytoPower Dietary Supplements for Gut and Digestive Health

This study is looking at how a dietary supplement system, called PhytoPower 1 and PhytoPower 2, affects gut and digestive health over eight weeks. It's for adults aged 18 to 80 who have gastrointestinal (GI) symptoms like bloating or discomfort. Researchers want to see if using these supplements daily can improve gut health. They will measure changes in your gut using stool tests that look at things like gut microbial diversity (the variety of bacteria in your gut) and specific markers of inflammation. The study plans to enroll about 50 participants and is currently unclear on its recruitment status.

Study design
This is an open-label, single-arm study, meaning all 50 participants will receive the PhytoPower supplements, and everyone will know what they are taking.
What's involved
You would take the PhytoPower 1 and PhytoPower 2 dietary supplements daily for eight weeks. Your gut and digestive health will be evaluated at the beginning and end of the study.
Compensation
Not stated in the trial record.
Follow-up
The study measures changes up to Week 8 (End of Study), so follow-up would be for this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07421596

An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System

Recruiting
NAAges 18–80InterventionalTreatment
SF Research Institute, Inc.
~50 participants
Updated 2026-02-24 on ClinicalTrials.gov
What's tested:PhytoPower 1 and PhytoPower 2

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Gut Microbial Diversity
Measured over Baseline (Day 1) to Week 8 (End of Study)
+10 more outcomes measured

Conditions

Gastrointestinal Symptoms
Digestive Health
Gut Health

Explore related trials

Gastrointestinal symptom

NCT07421596

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • San Francisco Research Institute

    San Francisco, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Dr. John Ademola
[email protected]
415-845-4638
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

1\. Male or female adults aged 18 to 80 years (considering 50% men and 50% women, even breakdowns in age groups 18-30, 31-60, 61-80 years, and 12-15% African American required) at the time of screening.

Exclusion

1\. Known allergy or hypersensitivity to any ingredient(s) of the study product or other herbal products.
Malabsorption disorders
Chronic gastrointestinal diseases
Severe depression
Clinically significant cardiovascular disease within the past 3 months 3. Pregnant, breastfeeding, or planning to become pregnant during the study period, based on subject self-report.
Proton pump inhibitors or antacids (e.g., omeprazole, Prilosec®)
Laxatives or gastrointestinal motility agents
Medications for irritable bowel syndrome (IBS), Crohn's disease, or history of hospitalized diverticulitis 14. Any other condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation or compromise subject safety or study integrity.

What this trial measures

  • Change in Gut Microbial DiversityBaseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in gut microbial diversity assessed using stool-based analysis as part of the Gut Zoomer® test.

  • Mean Change in Stool Calprotectin Concentration from Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool calprotectin concentration, a marker of intestinal inflammation, measured using the Gut Zoomer® test.

  • Mean Change in Stool Beta-Defensin 2 Concentration from Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool beta-defensin 2 concentration, an intestinal immune marker, measured using the Gut Zoomer® test.

  • Mean Change in Stool Secretory Immunoglobulin A (sIgA) Concentration from Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool secretory Immunoglobulin A (sIgA) concentration, an intestinal immune marker, measured using the Gut Zoomer® test.

  • Change in Digestive Function BiomarkersBaseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in digestive health biomarkers (short-chain fatty acids) assessed using stool-based analysis.

  • Mean Change in Stool Bile Acid Concentration From Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool bile acid concentration assessed using stool-based analysis.

  • Mean Change in Stool Malabsorption Marker Concentration From Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool-based markers of malabsorption assessed using stool-based analysis.

  • Mean Change in Stool Lipopolysaccharide (LPS) Concentration From Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool lipopolysaccharide (LPS) concentration assessed using stool-based analysis.

  • Mean Change in Stool Zonulin Concentration From Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool zonulin concentration assessed using stool-based analysis.

  • Mean Change in Stool Tissue Transglutaminase (tTG) Concentration From Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool tissue transglutaminase (tTG) concentration assessed using stool-based analysis.

  • Mean Change in Stool Anti-Gliadin Antibody Concentration From Baseline to Week 8Baseline (Day 1) to Week 8 (End of Study)

    Mean change from baseline to Week 8 in stool anti-gliadin antibody concentration assessed using stool-based analysis.